GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » FCF Margin %

HURA (TuHURA Biosciences) FCF Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. TuHURA Biosciences's Free Cash Flow for the three months ended in Sep. 2024 was $-1.89 Mil. TuHURA Biosciences's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, TuHURA Biosciences's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, TuHURA Biosciences's current FCF Yield % is -5.29%.

The historical rank and industry rank for TuHURA Biosciences's FCF Margin % or its related term are showing as below:


HURA's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -145.32
* Ranked among companies with meaningful FCF Margin % only.

TuHURA Biosciences FCF Margin % Historical Data

The historical data trend for TuHURA Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences FCF Margin % Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23
FCF Margin %
- - -

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24
FCF Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of TuHURA Biosciences's FCF Margin %

For the Biotechnology subindustry, TuHURA Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TuHURA Biosciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TuHURA Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where TuHURA Biosciences's FCF Margin % falls into.


TuHURA Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

TuHURA Biosciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-12.03/0
= %

TuHURA Biosciences's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-1.889/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TuHURA Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

TuHURA Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » FCF Margin %
Comparable Companies
Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
Website
https://www.tuhurabio.com
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.